EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Use of imaging biomarkers and ambulatory functional endpoints in Duchenne muscular dystrophy clinical trials: Systematic review and machine learning-driven trend analysis

Matthew Todd iD, Sanghoon Kang iD, Shunwen Wu, Devanand Adhin iD, Deok Yong Yoon iD, Rebecca Willcocks iD, Sarah Kim iD

Journal of Neuromuscular Diseases · 2025

DOI: 10.1177/22143602251360664 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Neuromuscular Diseases, 2025. Verfasst von Matthew Todd und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Machine Learning, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is a rare X-linked genetic muscle disorder affecting primarily pediatric males and leading to limited life expectancy. This systematic review of 85 DMD trials and non-interventional studies (2010–2022) evaluated how magnetic resonance imaging biomarkers—particularly fat fraction and T2 relaxation time—are currently being used to quantitatively track disease progression and how their use compares to traditional mobility-based functional endpoints. Imaging biomarker studies lasted on average 4.50 years, approximately 11 months longer than those using only ambulatory functional endpoints. While 93% of biologic intervention trials (n = 28) included ambulatory functional endpoints, only 13.3% (n = 4) incorporated imaging biomarkers. Small molecule trials and natural history studies were the predominant contributors to imaging biomarker use, each comprising 30.4% of such studies. Small molecule trials used imaging biomarkers more frequently than biologic trials, likely because biologics often target dystrophin, an established surrogate biomarker, while small molecules lack regulatory-approved biomarkers. Notably, following the 2018 FDA guidance finalization, we observed a significant decrease in new trials using imaging biomarkers despite earlier regulatory encouragement. This analysis demonstrates that while imaging biomarkers are increasingly used in natural history studies, their integration into interventional trials remains limited. From XGBoost machine learning analysis, trial duration and start year were the strongest predictors of biomarker usage, with a decline observed following the 2018 FDA guidance. Despite their potential to objectively track disease progression, imaging biomarkers have not yet been widely adopted as primary endpoints in therapeutic trials, likely due to regulatory and logistical challenges. Future research should examine whether standardizing imaging protocols or integrating hybrid endpoint models could bridge the regulatory gap currently limiting biomarker adoption in therapeutic trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneMachine LearningMagnetic Resonance ImagingHumansBiomarkersClinical Trials as TopicDisease Progression

Stichwörter der Autor:innen

Duchenne muscular dystrophyand machine learningclinical trialsfunctional endpointsimaging biomarkersrare diseasessystematic reviewtrend analysis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Department of Physical Therapy, University of Florida, Gainesville, FL, USA.

ORCID-Profile: Matthew Todd, Sanghoon Kang, Devanand Adhin, Deok Yong Yoon, Rebecca Willcocks, Sarah Kim

Förderung

  • NCATS NIH HHS

Zitieren

APA

Todd, M., Kang, S., Wu, S., Adhin, D., Yoon, D. Y., Willcocks, R., & Kim, S. (2025). Use of imaging biomarkers and ambulatory functional endpoints in Duchenne muscular dystrophy clinical trials: Systematic review and machine learning-driven trend analysis. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602251360664

Vancouver

Todd M, Kang S, Wu S, Adhin D, Yoon DY, Willcocks R, et al. Use of imaging biomarkers and ambulatory functional endpoints in Duchenne muscular dystrophy clinical trials: Systematic review and machine learning-driven trend analysis. Journal of Neuromuscular Diseases. 2025. doi:10.1177/22143602251360664

BibTeX
@article{Todd2025,
  author = {Todd, Matthew and Kang, Sanghoon and Wu, Shunwen and Adhin, Devanand and Yoon, Deok Yong and Willcocks, Rebecca and Kim, Sarah},
  title = {Use of imaging biomarkers and ambulatory functional endpoints in Duchenne muscular dystrophy clinical trials: Systematic review and machine learning-driven trend analysis},
  journal = {Journal of Neuromuscular Diseases},
  year = {2025},
  doi = {10.1177/22143602251360664}
}
Kostenlos starten →